Skip to main content
Premium Trial:

Request an Annual Quote

Genstruct Partners with Pfizer on Preclinical Drug Analysis

NEW YORK (GenomeWeb News) – Informatics company Genstruct said today it will collaborate with Pfizer on current and future preclinical drug safety studies.
Under a new master research agreement, Genstruct will initially work with Pfizer on a systems biology analysis of the biological mechanisms that underlie drug-induced liver injury.
Genstruct President and CEO Keith Elliston said the company has previously worked with Pfizer on oncology, vascular injury, cardiovascular, and metabolic disease.
Genstruct focuses on integrating and analyzing large-scale data from transcriptomic, proteomic, metabolomic, and phosphoproteomic research, Elliston said. The firm also applies its technologies to finding biomarkers of efficacy and toxicity of drugs.
Financial terms of the agreement were not released, but Genstruct said that it retains biomarker intellectual property rights.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.